Till sidans topp

Sidansvarig: Webbredaktion
Sidan uppdaterades: 2012-09-11 15:12

Tipsa en vän
Utskriftsversion

Cerebrospinal fluid bioma… - Göteborgs universitet Till startsida
Webbkarta
Till innehåll Läs mer om hur kakor används på gu.se

Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects.

Artikel i vetenskaplig tidskrift
Författare Leslie M Shaw
Hugo Vanderstichele
Malgorzata Knapik-Czajka
Christopher M Clark
Paul S Aisen
Ronald C Petersen
Kaj Blennow
Holly Soares
Adam Simon
Piotr Lewczuk
Robert Dean
Eric Siemers
William Potter
Virginia M-Y Lee
John Q Trojanowski
Publicerad i Annals of neurology
Volym 65
Nummer/häfte 4
Sidor 403-13
ISSN 1531-8249
Publiceringsår 2009
Publicerad vid Institutionen för neurovetenskap och fysiologi, sektionen för psykiatri och neurokemi
Sidor 403-13
Språk en
Länkar dx.doi.org/10.1002/ana.21610
Ämnesord Aged, Aged, 80 and over, Alzheimer Disease, cerebrospinal fluid, genetics, pathology, Amyloid beta-Protein, cerebrospinal fluid, Apolipoprotein E4, genetics, Area Under Curve, Biological Markers, cerebrospinal fluid, Cognition Disorders, cerebrospinal fluid, genetics, pathology, Cohort Studies, Diagnostic Imaging, Disease Progression, Female, Humans, Male, Middle Aged, Peptide Fragments, cerebrospinal fluid, Phosphorylation, ROC Curve, Retrospective Studies, Sensitivity and Specificity, Statistics, Nonparametric, Threonine, metabolism, tau Proteins, cerebrospinal fluid, chemistry
Ämneskategorier Medicin och Hälsovetenskap

Sammanfattning

OBJECTIVE: Develop a cerebrospinal fluid biomarker signature for mild Alzheimer's disease (AD) in Alzheimer's Disease Neuroimaging Initiative (ADNI) subjects. METHODS: Amyloid-beta 1 to 42 peptide (A beta(1-42)), total tau (t-tau), and tau phosphorylated at the threonine 181 were measured in (1) cerebrospinal fluid (CSF) samples obtained during baseline evaluation of 100 mild AD, 196 mild cognitive impairment, and 114 elderly cognitively normal (NC) subjects in ADNI; and (2) independent 56 autopsy-confirmed AD cases and 52 age-matched elderly NCs using a multiplex immunoassay. Detection of an AD CSF profile for t-tau and A beta(1-42) in ADNI subjects was achieved using receiver operating characteristic cut points and logistic regression models derived from the autopsy-confirmed CSF data. RESULTS: CSF A beta(1-42) was the most sensitive biomarker for AD in the autopsy cohort of CSF samples: receiver operating characteristic area under the curve of 0.913 and sensitivity for AD detection of 96.4%. In the ADNI cohort, a logistic regression model for A beta(1-42), t-tau, and APO epsilon 4 allele count provided the best assessment delineation of mild AD. An AD-like baseline CSF profile for t-tau/A beta(1-42) was detected in 33 of 37 ADNI mild cognitive impairment subjects who converted to probable AD during the first year of the study. INTERPRETATION: The CSF biomarker signature of AD defined by A beta(1-42) and t-tau in the autopsy-confirmed AD cohort and confirmed in the cohort followed in ADNI for 12 months detects mild AD in a large, multisite, prospective clinical investigation, and this signature appears to predict conversion from mild cognitive impairment to AD.

Sidansvarig: Webbredaktion|Sidan uppdaterades: 2012-09-11
Dela:

På Göteborgs universitet använder vi kakor (cookies) för att webbplatsen ska fungera på ett bra sätt för dig. Genom att surfa vidare godkänner du att vi använder kakor.  Vad är kakor?